Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Just three months after the results of two innovative and potentially cost-effective sequencing technologies were announced, one instrument has been launched on the market. Does this mean the $1,000 genome may be within sight? Jim Kling investigates.
With a growing need for better and more plentiful vaccines, traditional vaccine companies are responding by increasing manufacturing capacity, the biotech industry, with innovative products. Both are surely needed.
Reduced side effects and more effective therapies are some of the benefits promised by pharmacogenomics. But to reach these goals, industry will have to marshal a broad range of skills.
Even small biotech companies are taking more control of their product development as cash, competition, and other factors combine to bolster their negotiating power.